At $4.2M Shanghai Rolex Masters, China[R1] Florin Mergea (ROU)/ Rohan Bopanna (IND) bt Fabio Fognini (ITA)/ Rajeev Ram (USA) 62 retd.[R2] Florin Mergea (ROU)/ Rohan Bopanna (IND) vs (7) Vasek Pospisil (CAN)/ Jack Sock (USA)Rohan-Florin start their partnership with win … Their opponents retired after losing the first set … In the second round Rohan-Florin r facing 7th seed Pospisil-Sock.———————————————————–At […]
The Ebola virus has landed in the United States, after Thomas Eric Duncan flew from Liberia to Texas. He was released by a hospital in Dallas, despite telling hospital staff that he came from Liberia. He came in contact with up to 20 people, including 5 schoolchildren since touching down in Dallas. The CDC is monitoring these people, but I have […]
While biotech stocks saw an early selloff Friday, the shares of three companies in the sector have plenty of potential left, John Schroer of Allianz Global Investors said on CNBC.Biogen Idec is his top pick.”Leading company in the [multiple sclerosis] space. They have some very strong earnings growth, 20 to 25 percent earnings growth over the next three years. And […]
Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.Copyright ©2014 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.
Link:
Biotech Stocks 101 — What Investors Need to Know | InvestorPlace
[…]
Continue reading –
Shares of PacBio Tripled in 2013 Amid Strong Year for Biotech …
[…]
In 1996, fresh out Harvard, Rajiv Kaul went to work as an analyst covering biotechnology at Fidelity Investments. At the time, the sector was still considered a risky niche—the perfect project for the new guy. “Biotech was viewed like a lottery ticket,” says Kaul, 41. “It was something conventional investors shied away from.”
Where others saw uncertainty, Kaul saw possibility. After […]
In 1996, fresh out Harvard, Rajiv Kaul went to work as an analyst covering biotechnology at Fidelity Investments. At the time, the sector was still considered a risky niche—the perfect project for the new guy. “Biotech was viewed like a lottery ticket,” says Kaul, 41. “It was something conventional investors shied away from.”
Where others saw uncertainty, Kaul saw possibility. After […]
